According to the latest F-1/A Registration Statement filed on 2022-05-09 with US SEC:
"We have applied to have our Common Shares listed on the Nasdaq Capital Market under the symbol "AGNP" and recently received approval to list our Common Shares on Nasdaq Capital Market."
Yes, hard to find. I Hope for Positive news on Stroke, IPF/CC Data and Clinical Trials and Oncology for SCLC and Pancreatic/tumors. Certainly ALL need the Best efforts from our company teams to make a successful IPO.
In this company review of actions and challenges, I found this Bth 'device' reference? A reason for the NASH deal? Ending UF licensing.
"In regards to its medical device, the Company has certain direct competition from Menssana Research Inc., which is based in New Jersey, U.S. and Owlstone Nanotech Inc., which is based in the United Kingdom.
These companies have the financial ability to compete directly with the Company"
Agn IP now at Blo as some say? Cant find that. Any residual value?
...GLTA...
News 
Market Data 
Discover 
